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normal and cancer stem cells. Despite three decades of research that have elucidated the
transcriptional regulation, post-translational modifications and functions of Bmi-1 in regulating
the DNA damage response, cellular bioenergetics, and pathologies, the entire potential of a
protein with such varied functions remains to be realized. This review attempts to synthesize
the current knowledge on Bmi-1 with an emphasis on its role in both normal physiology and
cancer. Additionally, since cancer stem cells are emerging as a new paradigm for therapy resis-
tance, the role of Bmi-1 in this perspective is also highlighted. The wide spectrum of malig-
nancies that implicate Bmi-1 as a signature for stemness and oncogenesis also make it a
suitable candidate for therapy. Nonetheless, new approaches are vitally needed to further
characterize physiological roles of Bmi-1 with the long-term goal of using Bmi-1 as a prognostic
marker and a therapeutic target.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).TM, Ataxia telangiectasia mutated; BASC, bronchioalveolar stem cell; Bmi-1, B-cell specific Moloney
ncer initiating cell; CSC, cancer stem cell; EMT, epithelialemesenchymal transition; ESC, embryonic
ma; HDACi, histone deacetylase inhibitor; HSC, hematopoietic stem cell; hTERT, human telomerase
-helix; ISC, intestinal stem cell; MEC, mammary epithelial cell; NSC, neural stem cell; PcG, polycomb
glutamic acid, serine, and threonine; PRC, polycomb repressive complex; PTM, post-translational
new gene; Rb, retinoblastoma; TSC, trophectodermal stem cell; UTR, untranslated region; XEN,
harles Stephenson Cancer Center, OUHSC, 975 NE 10th Street, BRC-1409B, Oklahoma City, OK 73104,
5 271 7184; fax: þ1 405 271 2141.
harya@ouhsc.edu (R. Bhattacharya), Soumyajit-BanerjeeMustafi@ouhsc.edu (S. Banerjee Mustafi),
), Anindya-Dey@ouhsc.edu (A. Dey), Shailendra-Dwivedi@ouhsc.edu (S.K.D. Dwivedi).
f Chongqing Medical University.
15.04.001
ng Medical University. Production and hosting by Elsevier B.V. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
226 R. Bhattacharya et al.IntroductionIn the Em-myc transgenic mice, Bmi-1 (B cell-specific
Moloney murine leukemia virus integration site 1) was
discovered as a frequent target of the Moloney virus
insertion, resulting in virally accelerated B-lymphoid tu-
mors, hence its name.1 Since its discovery, Bmi-1 has been
implicated in a number of biological functions including
development, cell cycle, DNA damage response (DDR),
senescence, stem cell, self-renewal and cancer. Recently,
Bmi-1 has proven to be of significant clinical interest as it
has been noted to be overexpressed in a number of diseases
and malignancies. This review will seek to give a basic
overview of Bmi-1, its functions, and its potential research
and clinical implications.
Bmi-1 protein
The Bmi-1 gene localizes on chromosome 10 (10p11.23)
encodes for a 37 kDa protein composed of 326 amino
acids.2,3 Its protein structure is highly evolutionarily
conserved, demonstrating considerable homology with the
Mel-18 geneda transcriptional repressor of Bmi-1din
humans and the Posterior Sex Combs (Psc) protein in
Drosophila melanogaster.2,4
The functionality of the Bmi-1 protein is primarily char-
acterized by three regions: a central helix-turn-helix (HTH)
domain, a conserved RING finger domain at the N-terminal
end, and a carboxyl-terminal PEST-like domain.2,5,6 The
RING domain of Bmi-1 comprises of a three-stranded b-
sheet, two zinc binding loops, and an a-helix.5 The RING
domain is required for Bmi-1 to localize to DNA strand
breaks, thus critical for its role in DDR.7 Both the RING and
HTH motifs are necessary for prevention of senescence in
cells.8 Thus, these two regions aid in continuing the repli-
cative life span of cells. The HTH domain is also important in
binding Bmi-1 to DNA and providing a scaffold for subsequent
protein binding.9 PEST domains are protein regions rich in
proline (P), glutamic acid (E), serine (S), and threonine (T)
bounded by basic residues that tend to act as proteolytic
signals leading to protein degradation10. One study noted
that the PEST-like domain of Bmi-1 primarily contained
proline and serine residues and that the deletion of this re-
gion resulted in an increased half-life of Bmi-1 and promoted
the proliferation of cells.11
In addition to the three primary functional regions, the
Bmi-1 protein also contains two nuclear localization signals
(NLS): NLS1 and NLS2. Of these two, only NLS2 appears to
be functional in nuclear localization of Bmi-1 (Fig 1).12
PcG functionality
As a polycomb group (PcG) protein, Bmi-1 associates with
other PcG partners to function as an epigenetic repressor,
remodeling chromatin through histone 2A (H2A) mono-
ubiquitination and subsequent methylation at histones.3
PcG proteins were initially studied in Drosophila mela-
nogaster and identified as transcriptional repressors of Hox
genesdhomeotic genes that regulate morphogenesis and
tissue differentiation.13Consequently, PcG proteins have been studied in their
potential connection to cancer stem cells. Like stem cells in
healthy tissues, tumors appear to contain a small subset of
cells that have the potential to repopulate and affect
transcriptional regulation patterns. Since PcG proteins play
a role in transcriptional repression, it is hypothesized that
they may be highly involved in stem cell renewal and can-
cer development.14
There are two multimeric PcG protein complexes: Poly-
comb repressor complex 1 (PRC1) and Polycomb repressor
complex 2 (PRC2).3 As these complexes have been investi-
gated, core functional components have been determined
for both families of PcG proteins. In humans, the canonical
PRC1 is comprised of Bmi-1, RING1A/B, PCGF, CBX, and HPH,
while the core PRC2 is comprised of EZH, SUZ12, and EED.15
(summarized in Table 1). As a part of PRC1, Bmi-1 interacts
with RING1B via its own RING domain and enhances the E3
ubiquitin ligase activity to ubiquitinate histone H2A.5 PRC2
operates as a histone transmethylase that mono-, di-, and
trimethylates the Lys27 residue of histoneH3.16 Traditionally,
EED has only been associated with PRC2; however, a recent
study suggests that EED plays an important role in both PRC1
and PRC2, and thus may potentially be a key coordinator in
transcriptional regulation.17Mouse models
Murine and human Bmi-1 display a high degree of similarity at
the cDNA (92.4%) and at the protein level (98%), making mice
the primary model organism for Bmi-1.2 A definitive study
conducted by van der Lugt et al, demonstrated that Bmi-1
knockout mice are characterized by a survival rate of only
w50% by the third day after birth.4 Additionally, knockout
mice experienced increased frequency of illness, hemato-
poietic abnormalities in the liver and bonemarrow, lymphoid
abnormalities in the thymus and spleen, skeletal defects,
ataxic gait, and reduced density in cerebellum and neural
layers.4 Hematopoietic cell counts in the Bmi-1 knockout
mice were reduced to roughly 30% of wild-type levels and
continued to decrease as the mice aged. The majority of
thymocytes in the knockout mice were immature, with total
thymocyte levels being decreased to below 1%. In vitro, the
fetal hematopoietic cells tend to demonstrate considerable
growth defects, whereas in vivo the fetal cells developed
relatively normally and only displayed severe defects with
age. Despite the hematopoietic abnormalities, the red blood
cell count and associated blood parameters did not signifi-
cantly change in the knockout mice.18
A further study using Bmi-1 knockout mice found that
reactive oxygen species (ROS) increased in various cell
populations, especially thymocytes.19 In this study, the
Bmi-1 knockout thymocytes demonstrated diminished
oxidative capacity as well as reduced basal mitochondrial
oxygen consumptiondboth of which contributed to an
enhanced DNA damage response (DDR).19
An interesting Bmi-1 reporter study found that Bmi-1 is
highly expressed inquiescent intestinal stemcells (ISCs). Self-
renewal proteins Lgr5 and Bmi-1 were fluorescently tagged
within mice ISCs and were studied before and after irradia-
tion. Before irradiation, the Bmi-1 expressing ISCs were
characterized as quiescent,while theLgr5 ISCswere shown to
Figure 1 Bmi-1 Function and Protein Structure. (A) A visual representation of the known roles of Bmi-1. (B) Graphic of the Bmi-1
protein structure. Key protein motifs are indicated along with their relative sizes and locations. (HTH e helix-turn-helix; NLS e
nuclear localization signal; PEST e motif rich in proline, glutamic acid, serine, and threonine; RING e really interesting new gene).
Bmi-1: A comprehensive review 227be mitotically active. However, upon irradiation, the Lgr5
ISCs demonstrated susceptibility and died out quickly; in
contrast, the Bmi-1 ISCs displayed high resistance to irradia-
tion and proliferated to aid in regeneration. This ISC study
suggests that Bmi-1 expression in vivo is highly important
within injury response and regeneration of stem cells.20Transcriptional regulation
Transcription factors
Bmi-1 has a number of transcriptional and post-
transcriptional regulators. N-Myc, c-Myc, Sp1, Twist1,
FOXM1, E2F-1 and SALL4 have been shown to positivelyTable 1 Components of the PRC1 and PRC2 complexes.
Protein motif
PRC1
Bmi-1
Mel-18
CBX2, 6, 7, 8
CBX4
HPH1, 2
RING1A/B
SCMH1, SCML2
L3MBTL
RING domain5
RING domain28
Chromodomain144
Chromodomain144
Zinc finger and SEP domain145
RING domain5
Zinc finger, SAM and MBT domains146
MBT and SPM domains146
PRC2
EED
EZH1, 2
SUZ12
PCL1,2,3
JARID2
AEBP2
RBBP4, 7
YY1
WD40 domain17,148
SET domain149
Zinc finger149
PHD finger, TUDOR147
Zinc finger, ARID domain, JmjC and Jm
Zinc finger,147,149
WD40 domain147
Zinc finger150
Listed are the most common proteins that associate as part of PRC1 an
and how each protein contributesdif knowndto the complex as a w
AEBP e adipocyte enhancer-binding protein; ARID e AeT interactio
development; EZH e enhancer of zeste homolog; HPH e human poly
lethal(3)malignant brain tumor-like protein; MBT e malignant brain
retinoblastoma-binding protein; RING e really interesting new gene;
Su(var)3e9, enhancer-of-zeste; SPM e SCM, Ph, and MBT domain; SCMH
domain; SUZ e supressor of zeste; TUDOR e domain originally describe
aspartic acid repeat; YY e YineYang.regulate Bmi-1 expression, while KLF4, Mel-18 and histone
deacetylase inhibitors (HDACi) have been shown to suppress
expression at the transcriptional level.21e30 N-Myc and c-
Myc were shown to directly target and upregulate Bmi-1
mRNA in a dose-dependent manner.21 This mechanism
may occur by c-Myc binding to the enhancer box sequence
in the Bmi-1 promoter region.28 Zinc finger transcription
factor Sp1 was shown to directly interact with and upre-
gulate Bmi-1, possibly by binding to a G/C rich region.30
Twist1 has been shown to upregulate Bmi-1 in head and
neck squamous cell carcinomas through binding PRC2
components like EZH2.22 Forkhead box transcriptional fac-
tor FOXM1 transcriptionally stimulates genes implicated in
cell proliferation, and consequently positively regulates
Bmi-1 transcription.23 E2F-1 directly targets both Bmi-1 andFunction
E3 ubiquitin ligase5
Undetermined
Chromatin association,6,147
Chromatin association and sumolyation
E3 ubiquitin ligase5
jN147
PcG binding and stabilization14
Histone transmethylase144
Histone transmethylase151
Hypothesized147
Hypothesized147
Increases histone Transmethylase activity149,
Histone binding147
Recruits PcG proteins to DNA150
d PRC2. Also included are the important functional protein motifs
hole.
n rich domain; CBX e chromobox; EED e embryonic ectoderm
hometic homolog; JARID e Jumonji/ARID containing; L3MBTL e
tumor; PCL e polycomb-like; PHD e plant homodomain; RBBP e
SAM e sterile alpha motif; SEP e serine-glutamine-proline; SET e
e sex comb on midleg homolog; SCML e sex comb on midleg-like
d in Drosophila Tudor protein; WD40 e 40 residue tryptophan and
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late PRC2 components and Bmi-1, but no other PRC1 com-
ponents.24 Zinc finger transcription factor SALL4 positively
regulated the Bmi-1 promoter in a dose-dependent manner,
possibly through SALL4-induced hypermethylation at Lys4
on histone H3.25 Zinc finger protein KLF4 was shown to bind
to and repress Bmi-1 expression in colon cancer.26 Mel-18
reduces Bmi-1 expression by repressing Myc, a positive
regulator of Bmi-1.27,28 HDACi have been shown to repress
PRC2 components as well as Bmi-1 expression.29 While the
correlations between Bmi-1 transcription and these tran-
scription factors have been characterized, the exact
mechanisms and interactions of many of these transcription
factors still require further investigation.
Regulation by miRNA
MicroRNAs (miRNAs) are short 21e23 nucleotide RNA se-
quences that post-transcriptionally regulate gene expres-
sion. Bmi-1 expression is repressed by miRNAs in a number
of malignancies. We showed that miR-15 and miR-16
directly downregulated expression of Bmi-1 in ovarian
cancer.31 Within gastrointestinal cancer, miR-30e* has been
identified to suppress Bmi-1.32 miR-135a suppresses Bmi-1
expression in pancreatic ductal adenocarcinoma.33 miR-
141 induces senescence in diploid fibroblasts by repressing
Bmi-1, EZH2, and consequently, PRC1 and PRC2 activities.34
In melanomas, miR-203 has been shown to suppress Bmi-1
expression.35 And finally, miR-320a was shown to directly
target Bmi-1 and suppress its expression in nasopharyngeal
carcinoma.36 Together, these reports indicate that
depending on the cancer context a variety of miRNAs target
the Bmi-1 mRNA, nonetheless suggesting the importance of
Bmi-1 in various malignancies.
Post-translational modifications
Post-translational modification (PTM) of Bmi-1 is a rela-
tively under-explored field and is directly associated with
the functionality of the protein. Several PTMs of Bmi-1 have
been reported, of which sumoylation, phosphorylation,
acetylation and ubiquitination are of particular interest.
Although the reports related to each such modification are
limited and restricted to tissue and/or cancer types, it is
interesting to note the diversity in the functional alteration
that each such modification induces. The following para-
graphs will further discuss how site-specific phosphoryla-
tion of Bmi-1 by different kinases, influence its
tumorigenicity both positively and negatively.
Acetylation has been shown to influence the nuclear
arrangement and function of the Bmi-1. Through time-lapse
confocal microscopy, micro-irradiation by UV laser
(355 nm), and GFP technology, the dynamics and recruit-
ment of Bmi-1 to UV-damaged chromatin were studied.
Bmi-1 was rapidly recruited (half-time t1/415 s), suggesting
that Bmi-1 might be required for recognition of UV-
damaged sites.37 Histone hyper-acetylation, stimulation
by HDACi/TSA, suppression of transcription by actinomycin
D, and ATP-depletion were all shown to prevent increased
accumulation of Bmi-1 to gH2AX-positive irradiated chro-
matin.37 While there was no direct evidence of acetylatedBmi-1, this demonstrated that the nuclear arrangement of
Bmi-1 was influenced by acetylation and occurred as an
early event prior to the recruitment of HPb to the UV-
irradiated chromatin.
CBX4, a component of the PRC1, has also been shown to
accumulate at sites of DNA damage as a part of the DDR
pathway. A novel role for CBX4 as an early DDR protein
involved SUMO conjugation at sites of DNA lesions.38 DNA
damage stimulates sumoylation of Bmi-1 by CBX4 at Lys88,
which is required for the accumulation of Bmi-1 at DNA
damage sites.38 Moreover, CBX4 recruitment to the sites of
laser micro-irradiation-induced DNA damage requires PARP
activity but does not require H2AX, RNF8, Bmi-1 nor PI-3-
related kinases.38 The importance of CBX4 in the DDR was
confirmed by the depletion of CBX4, which resulted in
decreased cellular resistance to ionizing radiation.38 Both
the studies interestingly indicated that a PTM of Bmi-
1deither acetylation or sumoylationdis an important
prerequisite for recruitment of Bmi-1 to initiate the DDR
pathway.
Several groups have simultaneously reported on phos-
phorylation of Bmi-1. Phosphorylated Bmi-1 at different
serine residues modified both the Ink4a/Arf dependent and
independent functions. As a PcG protein, Bmi-1 is phos-
phorylated by 3 pK (MAPKAP kinase 3), which is a conver-
gence point downstream of activated ERK and p38 signaling
pathways that have been implicated in differentiation and
developmental processes.39 In vitro and in vivo
experimentsdas well as yeast two-hybrid interaction and
co-immunoprecipitationdestablished 3 pK as an interact-
ing partner of PRC1 via Bmi-1.39 Gain of 3 pK activity-
deither through genetic or pharmacological
interventiondresulted in phosphorylation of Bmi-1 and
other PcG members, and in their dissociation from chro-
matin, culminating in de-repression of targets. One such
reported Bmi-1 target is the Cdkn2a/Ink4A locus. Cells
overexpressing 3 pK showed PcG complex/chromatin
dissociation and concomitant de-repression of p14Arf, which
was encoded by the Cdkn2a/Ink4A locus. Thus, 3 pK is a
candidate regulator of phosphorylation-dependent PcG/
chromatin interaction.39
Bmi-1 was also reported to be phosphorylated by PI3K/
Akt pathway.40 Both Bmi-1 and Akt were coactivated in a
substantial fraction of human high-grade tumors. Akt
mediated Bmi-1 phosphorylation, enhanced its oncogenic
potential in an Ink4a/Arf-independent manner.40 This pro-
cess also modulated the DDR and affected genomic stabil-
ity. These experiments placed Bmi-1 in a close niche of
cellular signaling networks, opening up a world of possi-
bilities as to how external signaling stimulidin collabora-
tion with chromosomal modifications through the Bmi-1/
PRC1 complexdcan dictate an oncogenic outcome.40
These data have direct bearing in providing new mecha-
nistic insights into the modulation of Bmi-1 function by
phosphorylation, either by 3 pK or by Akt.
Another independent study showed that phosphorylation
of Bmi-1 by Akt could also modulate its function through
the Ink/Arf pathway. Phosphorylation of human Bmi-1 at
Ser316 by Akt impaired its function by triggering dissociation
from the Ink4a/Arf locus, which resulted in decreased
ubiquitination of histone H2A and the inability of Bmi-1 to
promote cellular proliferation and tumor growth.41
Figure 2 Role of Bmi-1 in Ink4a/Arf Pathway. This figure
shows how PRC1 component Bmi-1 helps in the mediation of
transcriptional repression at the Ink4a/Arf locus. This mecha-
nism leads to downstream repression of cell cycle and onco-
genic pathways.
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inhibited its ability to promote self-renewal of hemato-
poietic stem and progenitor cells. These studies provide a
mechanism for the increased abundance of p16Ink4a and
p14Arf observed in cancer cells with an activated phos-
phoinositide 3-kinase (PI3K)/Akt signaling pathway, and
identify crosstalk between phosphorylation events and
chromatin structure. Together these reports point to the
context dependent variability in functional outcome of
phosphorylated Bmi-1.
Other important aspects of modulating Bmi-1 function
are through the alteration in protein stability via ubiquiti-
nation. A recent study by Sahasrabuddhe et al, identified
that Bmi-1 contains a functional recognition motif for the F
box protein bTrCP, which regulates ubiquitination and
proteasome-mediated degradation of various proteins.
Overexpression of wild-type bTrCPdbut not the DF muta-
ntdpromoted Bmi-1 ubiquitination and degradation. Also,
compared to wild-type Bmi-1, the DF mutant protein
exhibited increased pro-oncogenic activity.42 In summary,
this finding establishes the importance of ubiquitination of
Bmi-1 in regulating the turnover of Bmi-1 and its functional
relevance in oncogenesis.
Regarding the existing data on PTMs of Bmi-1, it appears
that the field is still at a nascent stage and further evidence
needs to be accumulated to fully elucidate the diversified
role of Bmi-1 in various physiological processes. However, it
is not premature to speculate that PTMs of Bmi-1 are most
likely cancer-tissue specific and that the specific site
largely dictates the unique physiological role that this
protein plays.
Bmi-1 in cellular physiology
Development
As previously noted, the PcG complexes were first identi-
fied as trans-acting regulators of homeotic gene function in
Drosophila.43 Two clusters of homeotic genes, the anten-
napedia complex and the bithorax complex, collectively
referred to as the homeotic complex are responsible for the
determination of segmental identities in Drosophila. In
vertebrates, PcG complexes regulate the self-renewal of
various types of embryonic and adult stem cells44,45 as well
skeletal malformations.46,47 PcG proteins are also evolu-
tionarily conserved chromatin modifiers that can tran-
scriptionally silence their targets through many rounds of
cell division during development. Bmi-1 is arguably the PcG
protein most strongly associated with neoplastic
development.48
Bmi-1 plays an important role in morphogenesis during
embryonic development and in hematopoiesis throughout
pre- and post-natal life. In most tissues, low levels of the
Bmi-1 mRNA are detected, whereas higher mRNA levels are
found in thymus, heart, brain, and testes. Bmi-1 is also
expressed in embryonic stem cells (ESCs) during embryonic
development and in the placenta. Bmi-1 has an important
role in anterioreposterior axis specification and in main-
taining the correct spatial Hox gene expression pattern.49,50
Loss of function of Bmi-1 has pleiotropic effects. Mice
lacking Bmi-1 exhibit a homeotic posterior transformationcoupled with strong proliferative defects during lympho-
cyte development, and also neurological abnormalities.4 In
absence of Bmi-1, primary embryonic fibroblasts are unable
to progress into S phase and to undergo premature senes-
cence.51 Bmi-1 functions in normal development and stem
cell maintenance have been attributed to its transcrip-
tional repression of the Ink4a/Arf locus (Fig 2).45,52,53 In the
central and peripheral nervous system, Bmi-1 deficiency is
associated with increased expression of p16Ink4a and p19Arf,
and inactivation of p16Ink4a in Bmi-1/ mice partially
rescued the self-renewal defect of Bmi-1/ neural stem
cells (NSCs).54 The PcG members are dynamically expressed
throughout pre-implantation and development.55,56
Recently Lavialy et al, reported a regulatory pathway that
underlies cell fate allocation during early development.
This process mechanistically links Bmi-1 to the lineage-
specific transcription factors Nanog and Gata6.57 Bmi1 is
repressed by Nanog in ESCs and highly expressed in the
extraembryonic endoderm (XEN) and trophectodermal stem
cells (TSCs) where Nanog is not present. Bmi-1 physically
interacts with Gata6 in extraembryonic primitive endoderm
derived XEN cells and controls its protein stability and
resultant activity by inhibiting Gata6 ubiquitination and
proteasome-mediated degradation. Interestingly, Bmi-1
also interacts with and maintains high Gata3 protein
levels in TE-derived TSCs,58 suggesting a broader function
for Bmi-1 in extraembryonic lineage formation and
maintenance.
Cell cycle
The normal cell cycle progression and regulation is tightly
controlled by a variety of molecular checkpoints that su-
pervise the various biological functions of the cell that
occur within the different phases of the cell cycle.59 Bmi-1,
being a transcriptional repressor and PcG protein, plays an
important role in cell cycle regulation.4 Bmi-1 controls self-
renewal and cell cycle by regulating the tumor suppressor
230 R. Bhattacharya et al.proteins p16Ink4a and p14Arf.60,61 Bmi-1 promotes CDK4 and
CDK6 activity by repressing the Ink4a/Arf locus, which en-
codes the CDK4/6 inhibitor p16Ink4a and p19Arf (a homolog of
human p14Arf) that activates p53 (Fig 2).51 Bmi-1 can also
directly regulate p53 stability, further stressing its role in
cellular proliferation and tumorigenesis by negatively
acting through the pRb-p53 pathway.62,63 The p16Ink4a pro-
tein inhibits binding of Cyclin D to CDK4/6, resulting in the
suppression of retinoblastoma (Rb) activity and induction of
cell cycle arrest.51,60 p19Arf induces p53 and causes cell
cycle arrest.51,64 Bmi-1 promotes cell proliferation by sup-
pressing p16Ink4a/Rb and/or p14Arf/MDM2/p53 tumor sup-
pressor pathways.51 The absence of Bmi-1 is reported to
relieve the repression of the Ink4a, resulting in the
expression of p16Ink4a and p14Arf. Bmi-1 abolishes cell cycle
checkpoints p16/p14 in various cell types.3 The cell cycle
checkpoint that involves the Ink4a/Arf-p53-pRb axis has
been described as the principle barrier to the initiation and
maintenance of neoplastic transformation.65,66
In contrast, a few studies have also reported that the
proto-oncogene Bmi-1 is required for hepatocellular carci-
noma (HCC) cell proliferation; however, the effect of Bmi-1
in promoting HCC cell growth was independent of the
Ink4a/Arf status.67e69 The crosstalk among the proteins
active in these pathways and in the epigenetic control of
Ink4a/Arf expression has been widely investigated to
characterize the role of proto-oncogenes that negatively
affect this molecular checkpoint.70,71 The down-regulation
of Bmi-1 also inhibits HCC cell growth independent of
Ink4a/Arf status. In mouse tumor cells induced by Bmi-1/
RasV12, there is no down-regulation of p16Ink4a or p19Arf
expression.72 A recent report evidenced that PRCs regulate
cellular proliferation and transformation independently of
the Ink4a/Arf-pRb-p53 pathway. PRCs localize at replica-
tion forks, and the loss of their function directly affects the
progression and symmetry of DNA replication forks.73 Ink4a
proteins function as antagonists of the Cyclin DeCDK4/6
complex, thereby hindering phosphorylation of Rb family
members and consequent entry into S phase. p19Arf, in
contrast, is not a CDK inhibitor and instead positively reg-
ulates p53.52 Deletion of both p16Ink4a and p19Arf through
the disruption of the entire Ink4a locus has minimal con-
sequences for HSC activity. Their limited expression is likely
the result of transcriptional repression by Bmi-1, which is
expressed preferentially in HSCs and actively represses the
Ink4a locus.18,74 Bmi-1 deficiency is lethal in adult mice due
to hematopoietic failure caused by a progressive depletion
of HSCs.18,74 The escalation in p16Ink4a and p19Arf expression
caused by Bmi-1 removal may completely inhibit the
infrequent cell cycle entry of adult HSCs, which is crucial
for HSC self-renewal and maintenance of blood homeosta-
sis. Recent reports also suggested that Bmi-1 controls
mouse glioma development in an Ink4a/Arf independent
manner.69 Bmi-1 knockdown significantly inhibits cell
growth in both wildtype and p16Ink4a null Ewing sarcoma67
and medulloblastoma cell lines.75 Thus, although inhibi-
tion of Ink/Arf tumor suppressor gene expression has been
widely considered to be the key mechanism for the onco-
genic activity of Bmi-1, more recent data suggest a critical
role of Ink/Arf independent mechanisms for Bmi-1 during
carcinogenesis.DNA damage response
Genome integrity is constantly challenged by endogenous
(metabolic) and exogenous (environmental) sources. To
combat threats posed by DNA damage, cells have evolved
mechanisms that are collectively termed as DDR. DDR in-
volves a plethora of proteins whose sequential recruitment
and function at DNA damage sites are modulated by
numerous highly dynamic and reversible PTMs, including
phosphorylation, ubiquitination, acetylation, methylation
and sumoylation.
Bmi-1 is known to play a key role not only in preventing
DNA damage, but also in DDR. Mitochondrial ROS has been
known to be a prominent agent for oxidative DNA damage.
Liu et al, has demonstrated that independent of p16Ink4a,
Bmi-1 has a role in maintaining mitochondrial function and
redox homeostasis.19 Further, cells lacking Bmi-1 have sig-
nificant mitochondrial dysfunction accompanied by a sus-
tained increase in ROS that is sufficient to engage the DDR
pathway.19 We also have shown that silencing Bmi-1 in
ovarian cancer model leads to increased ROS generation
that induces PARP cleavage and apoptosis. Thus, Bmi-1
prevents oxidative DNA damage.76
Apart from protecting against oxidative DNA damage,
Bmi-1 has been shown to be a key component in DDR, as it is
required and sufficient to recruit the DDR machinery to DNA
double-strand break (DSB) sites in response to radiation and
can prolong NSC survival.77 Facchino et al, have shown that
Bmi-1 is enriched at the chromatin after irradiation,
localized and co-purified with ataxia telangiectasia
mutated (ATM) protein and gH2AX. Bmi-1 was also shown to
preferentially co-purify with non-homologous end joining
proteins DNA-PK, PARP-1, hnRNP U, and histone H1 in
CD133þ glioblastoma cells.77
Following DNA damage, Bmi-1 tethers RING finger pro-
tein 2 (RNF2 or RING1B) to DNA, and associates more stably
with damaged compared to undamaged chromatin.78
Computational models based on a recently derived crystal
structure of Bmi-1eRING1Beubiquitin-conjugating enzyme
H5c (UbcH5c) suggest that the complex binds to both
nucleosomal DNA and histone H479, whereas initial
recruitment of RING1BeBmi-1 to DSBs is dependent on
sumoylation of Bmi-1.38 As previously discussed, the PRC1
complex member CBX4 promotes sumoylation (SUMO-1) of
Bmi-1 at Lys88 (K88), while the Bmi-1 K88R mutant failed to
be recruited to the repair foci.38 RING1BeBmi-1 catalyzes
mono-ubiquitination of H2AX/H2A at Lys119 and Lys120
(Lys118 and Lys119 in H2A).7,80e82 This modification is
essential for the recruitment of ATM to damage site, and
consequently, is necessary for efficient formation of g-
H2AX.81,82 Although Bmi-1 is required for initial recruitment
of ATM, ATM is required for sustained localization of Bmi-1
at breaks, which is important for efficient homologous
recombination.7
Further experimentation will be required to dissect the
mechanism by which sumoylation mediates RING1BeBmi-1
assembly at DSBs, and how H2AX ubiquitination enables
binding of ATM. Initial studies suggest that ubiquitination of
H2A may weaken interaction with DNA, destabilizing the
nucleosome,83 thus helping in binding of other DDR
proteins.
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damage along with facilitating DDR, Bmi-1 contributes to
maintaining genome integrity and resistance to genotoxic
therapeutic reagents. Since the efficacy of cancer chemo-
therapy and radiotherapy relies on generation of DNA
damage that is recognized and repaired by intrinsic DNA
repair pathways, high expression of Bmi-1 correlates with
therapy failure and could be a biomarker for resistance of
DNA damaging therapy. Along these lines Sauvageau et al,
showed that transformed human cell lines as well as
primitive hematopoietic cells exhibited a high frequency of
spontaneous chromosome breaks upon Bmi-1 depletion and
were hypersensitive to genotoxic agents. Bmi-1 was
recruited rapidly to the DNA damage foci where it blocked
transcriptional elongation. In addition, Bmi-1 was required
for homologous recombination repair and checkpoint
recovery.84Senescence and stem cells
Cellular senescence is characterized by an irreversible cell
cycle arrest often in response to acute insults in an attempt
to prevent damaged or mutated cells from proliferating
uncontrollably.85 Histone deacetylase-associated Sin3B
protein is implicated in cell cycle withdrawal, where it is
transcriptionally upregulated.86 Sin3B has been identified
as a novel direct target of Bmi-1, where Bmi-1-driven
repression of Sin3B as an essential regulator of cellular
senescence has been proposed.87 Bmi-1 has also been re-
ported to prevent senescence and immortalize cells
through the activation of telomerase in breast cancer
cells61 and ovarian cancer cells, where elevation of Bmi-1
expression is closely correlated to the increased telome-
rase activity.88 Human telomerase reverse transcriptase
(hTERT) expression, which leads to induction of telomerase
activity is a direct target of c-Myceinduced transcription in
mammary epithelial cells (MECs)89,90 Apparently, Bmi-1,
being a transcriptional repressor, acts independently from
c-Myc. These data suggest that Bmi-1 regulates telomerase
expression in MECs and might play a role in the develop-
ment of human breast cancer. Deletion analysis of the Bmi-
1 protein suggested that the RING finger, as well as a
conserved HTH domain, were required for its ability to
induce telomerase and immortalize MECs.61 However, Bmi-
1 induction of telomerase is cell type specific; Bmi-1 fails to
induce telomerase in fibroblasts.61 This is consistent with
the observation that Bmi-1 overexpression did not immor-
talize human fibroblasts.8 It is not known whether Bmi-1 is
involved in telomere function in normal breast stem cells.
However, in the fetal liver, Bmi-1 was reported to play
equally important roles both in the normal as well as pro-
genitor stem cells.91 Hosen et al, showed that the expres-
sion of Bmi-1 is high in primitive HSCs, and is decreased
when HSCs are differentiated into a particular lineage.92
The self-renewal and maintenance of HSCs and NSCs were
reported to depend on the levels of Bmi-1.60,64 These re-
ports suggest a strong correlation between Bmi-1 and the
differentiation and renewal of stem cells.
Bmi-1 is reported to play a crucial role during the self-
renewal and maintenance of prostate, intestinal, lung
epithelial and bronchioalveolar stem cells.93e95 It wouldnot be out of place to underscore the commonality be-
tween stem cells and cancer cells to micromanage the
bioenergetic needs for influencing epigenetic/genetic pro-
grams. Stem cells are characterized by well classified en-
ergetic and biosynthetic demands compared to quiescent
differentiated cells.96 Changing gears between the glyco-
lytic and mitochondrial oxphos pathways triggers differen-
tiation or reprogramming to pluripotency that are
furthermore accompanied by consequent changes in cell
cycle, biomass, metabolite levels, and redox state. So
either a direct or indirect role of Bmi-1 in regulating the
cellular bioenergetics may be well conceived as a strategy
to answer how Bmi-1 integrates with epigenetic and genetic
programs to coordinately regulate stem cell lineage and/or
fate.
Stem cells are of two types: ESCs and adult stem cells
(ASCs). ESCs are pluripotent stem cells capable of devel-
oping into different cells; while ASCs maintain and repair
their resident tissues in adult organisms. Thus, self-
renewal, differentiation, and prevention of senescence of
ASCs are critical for tissue homeostasis. Aging is the pro-
gressive decline in physiology and function of adult tissues
often attributable to the loss of regenerative capacity of
ASCs.97 ASCs play key roles in overall tissue homeostasis and
repair. The function of ASCs declines with age, which may
contribute to the physiological decline in tissue homeo-
stasis and the increased risk of neoplasm during aging.
Control of gene expression by chromatin remodeling is
critical for ASC function.98
Bmi-1 plays a crucial role in self-renewal and differen-
tiation of leukemic stem and progenitor cells. In breast
cancer cells, gain of Bmi-1 function resulted in increased
self-renewal and promoted epithelialemesenchymal tran-
sition (EMT), while contrasting phenotypes were reported
with Bmi-1 knockdown through regulation of Nanog
expression via the NFkB pathway.99
In the nervous system, Bmi-1 is also required for the self-
renewal of adult NSCs. Both constitutive deletion and acute
knockdown of Bmi-1 result in impaired self-renewal of
cultured NSCs isolated from young adult mice. The effect of
Bmi-1 knockdown on NSCs is aggravated if NSCs are isolated
from adult as opposed to embryonic and postnatal mice.
In vivo, Bmi-1 deficiency causes a decrease in the numbers
of proliferating, bromodeoxyuridine positive SVZ cells
(neural progenitors) without affecting apoptosis.54,100
In addition to modulating the self-renewal of stem cells,
Bmi-1 regulates stem cell differentiation potential in both
HSCs and NSCs. Loss of Bmi-1 does not block the differen-
tiation of more committed hematopoietic progenitors,51,101
but affects the ability of stem cells and early progenitors to
retain all cell fate choices. In culture, HSCs from young
adult Bmi-1-deficient mice have reduced multi-lineage
potential compared with wild-type HSCs when assessed at
early passage.101 The effects of Bmi-1 on HSC differentia-
tion have been linked to its effects on chromatin state. In a
mixed population of HSCs and multipotent progenitors
(IL7Ra/KLS), Bmi-1 binds at genomic loci that are marked
by both repressive H3K27me3 and active H3eK4me3,102 a
‘bivalent’ chromatin state associated with genes that are
poised to be expressed during differentiation.103 Constitu-
tive loss of Bmi-1 in the HSC/multipotent progenitor pop-
ulation results in a reduction in H3K27me3 binding, de-
232 R. Bhattacharya et al.repression of B-cell lineage factors and consequent in-
crease in B-lymphopoiesis.102 Thus, Bmi-1 is a promising
candidate for the regulation of HSC differentiation poten-
tial during aging. Bmi-1 function in young adult HSC and NSC
self-renewal is mediated, in large part, through its tran-
scriptional repression of the p16Ink4a/p19Arf aging locus.51
p16Ink4a inhibits Cyclin-D/CDK4/6 complexes to control
cell cycle and senescence, whereas p19Arf contributes to
cell cycle control, senescence and apoptosis through the
regulation of p53.104
Genetic experiments suggest that in HSCs, p16Ink4a is the
dominant mediator of the effects of Bmi-1 on stem cell
proliferation. Deletion of the entire p16Ink4a/p19Arf locus,
but not that of p19Arf alone, can mostly rescue the effect of
Bmi-1 deficiency on HSC self-renewal in long-term
competitive repopulation assays.105 p19Arf may be a more
critical target in adult NSCs, as p19Arf deletion partially
rescues self-renewal defects caused by Bmi-1 deficiency,
although to a lesser extent than deletion of the entire
p16Ink4a/p19Arf locus.64,106 In contrast to chronic Bmi-1 loss,
acute RNA interference-mediated knockdown of Bmi-1 in
NSC cultures from young adult mice does not lead to an
increase in p16Ink4a or p19Arf expression, but instead results
in altered expression of another cell cycle inhibitor,
p21CIP1, which can rescue the anti-proliferative phenotype
of Bmi-1 knockdown.107 Thus, acute loss of Bmi-1 is likely
insufficient for bringing about quick changes to the chro-
matin state of the p16Ink4a/p19Arf locus; however, consti-
tutive deletion of Bmi-1 may result in gradually
accumulating and stably maintained activating chromatin
marks, such as H3K4me3 or histone acetylation, at the
p16Ink4a/p19Arf locus.
The expression of Bmi-1 itself does not change signifi-
cantly in isolated HSC and NSC populations during
aging.108,109 By contrast, the role of Bmi-1 in maintaining
self-renewal and multipotency notably declines during
aging, arguing for altered activity of Bmi-1 at yet uniden-
tified targets. Indeed, growing evidence proposes addi-
tional age-related targets for Bmi-1 in addition to p16Ink4a/
p19Arf. Overexpression of Bmi-1 in HSCs isolated from p19Arf
mutant mice and p16Ink4a/p19Arf compound mutant mice
can still enhance multipotency of HSCs in vitro.101,105
Furthermore, Bmi-1 plays a non-cell autonomous role in
the bone marrow microenvironment that does not depend
on p16Ink4a or p19Arf.105 Similarly, deletion of the entire
p16Ink4a/p19Arf locus in Bmi-1/ mice does not completely
rescue NSC defects in self-renewal capacity.64,106
The p16Ink4a/p19Arf-independent requirement for Bmi-1
in ASC populations may be due to the ability of Bmi-1 to
regulate the DDR pathway via repression of the cell cycle
checkpoint protein Chk2.19 Deletion of Chk2 in Bmi-1/
mice restores hematopoietic stem and progenitor cell func-
tion and enhances progenitor cell proliferation.19 These re-
ports suggest that modulators of chromatin state, such as
Bmi-1, are crucial for maintaining the ability of ASCs to
integrate and respond to environmental stresses during
aging.
Overexpression of p16Ink4a and p19Arf in adult HSCs
induced cell cycle arrest and apoptosis via the pRb and the
p53-dependent pathway, respectively. Double deletion of
the Bmi-1 and p16Ink4a/p19Arf genes partially rescued the
phenotypes observed in Bmi-1-deficient mice,51 suggestingthat p16Ink4a, p19Arf, and p53 are downstream effectors of
Bmi-1 that are involved in the control of the proliferation
and survival of HSCs during self-renewing cell divisions.
In cancer, recurrence after optimal treatment has often
been a critical clinical limitation indicative of the existence
of another emerging stem cell category that evaded the
existing therapy, classified as cancer initiating cells (CIC) or
cancer stem cells (CSC). Evidence of CSCs from xenograft
models and surviving fraction of treated tumors further
consolidate this theory. Therefore, the stemness properties
of CICs pose a new challenge to existing cancer therapy and
from different studies, Bmi-1 surfaces as a bio-signature of
these CIC/CSC.110e112 The complex dynamics of Bmi-1
function ranging from cell cycle regulation, stem cell
maintenance to DDR extends beyond its capacity as a
transcriptional repressor of the Ink/Arf pathway. It can be
speculated that as future research brings into light
new interactors of Bmi-1, many other cellular processes
would be discovered in which Bmi-1 plays an important
role.Cancer
As previously noted, Bmi-1 was first identified as a Myc-
cooperating oncogene in murine B- and T-cell lym-
phomas.61,74,113,114 Several recent studies have suggested
that in human cancers, Bmi-1 is often overexpressed and
acts as an oncogene to promote carcinogenesis including
prostate, lung, ovarian, urinary bladder, lymphoma, me-
sothelioma, medulloblastoma, glioma, acute myeloid leu-
kemia and breast cancer.115 Bmi-1 overexpression drives
stem-like properties associated with induction of EMT that
promotes invasion, metastasis, and poor prognosis.51,61 This
section summarizes (Table 2) the critical roles of Bmi-1 in
all reported types of cancer to date.
Glioblastoma: Bmi-1 has been shown to be essential for
the proliferation and self-renewal of the NSCs of the sub-
ventricular zone.18,54,64,100,106,116,117 Also, Bmi-1 is neces-
sary for the propagation of leukemic stem cells and is
expressed in glioblastoma stem cells.74,118 Ha¨yry et al, have
shown that Bmi-1 is expressed in all histological types of
gliomas and that relative protein expression is a novel in-
dependent prognostic marker in oligodendroglial tumors.119
Bmi-1 is overexpressed in human glioblastomas and is highly
enriched in the tumor-initiating CD133þ stem cells.
Knockdown of Bmi-1 completely prevented brain tumor
formation in mice.120 miR128 has also been shown to
negatively regulate Bmi-1 expression and inhibits self-
renewal of glioma.121
Medulloblastomas: Bmi-1 is strongly expressed in
proliferating cerebellar precursor cells in mice and
humans.117 Overexpression of Bmi-1 promotes cell prolif-
eration and is required for the hedgehog pathway-driven
tumorigenesis in medulloblastomas. Sonic hedgehog (Shh)
modulates Bmi-1 in childhood medulloblastoma brain
tumor-initiating cells. Bmi-1 expression positively corre-
lates with increasing Shh ligand concentrations.122
Ovarian cancer: Bmi-1 is highly expressed in ovarian
epithelial cancer tissues, and its expression level correlates
with histological grade and clinical phase of the patients.31
We had previously found that inhibition of the Shh pathway
Table 2 Known roles of Bmi-1 in cancer.
Cancer Role of Bmi-1 Reference
Breast Bmi-1 plays a crucial role in invasion and metastasis by modulating the Akt/GSK-3b/Snail
pathway and the expression of EMT markers in breast cancer
130,131
Colorectal Bmi-1 regulates histone ubiquitination for colon cancer proliferation in vitro and in vivo 132,26
Glioblastoma Bmi-1 overexpressed in human glioblastoma tumors and highly enriched in tumor-initiating
CD133þ stem cells
120
Head and neck Bmi-1 directly regulates the EMT regulator, Twist1 128
Hepatic Bmi-1 is upregulated in human hepatocellular carcinoma in an Ink4a/Arf-independent manner
in liver cancer development
72
Intestine Bmi-1 deficiency impairs the progression and maintenance of small intestinal tumors in a cell
autonomous and highly Arf-dependent manner.
134
Leukemia Bmi-1 is highly expressed in M0-subtype acute myeloid leukemia 135,136
Lung Bmi-1 is required for the self-renewal of the lung epithelial stem cells and bronchioalveolar
stem cells
138,139
Lymphoma Bmi-1 can contribute to lymphomagenesis in the T and B cell lineages and collaborate with the
Myc gene in tumor development
152
Medullo-blastomas Bmi-1 is strongly expressed in proliferating cerebellar precursor cells in mice and humans. 117
Naso-pharyngeal
carcinoma
Bmi-1 is highly overexpressed which lead to the induction of telomerase activity, reduction of
p16Ink4a expression, and immortalization of nasopharyngeal epithelial cells
125
Ovary Bmi-1 protein is highly expressed in ovarian epithelial cancer tissues 31,88
Pancreatic cancer Bmi-1 is overexpressed in human pancreatic cancer 153
Prostate Bmi-1 is a crucial regulator of self-renewal in adult prostate cells and plays important roles in
prostate cancer initiation and progression
93
Skin Bmi-1 levels are markedly elevated in epidermis-derived cell lines and in epidermal squamous
cell carcinoma
140
Tongue Bmi-1 is abnormally overexpressed in tongue cancers, which is associated with cervical node
metastasis.
141
This table gives a brief overview of the reported functions of Bmi-1 in progression and maintenance of human cancers.
EMT e epithelialemesenchymal transition.
Bmi-1: A comprehensive review 233by cyclopamine inhibited sub-cutaneous ovarian tumor
growth and potently downregulated Bmi-1 at the protein
level.123 Elevation of Bmi-1 expression is closely correlated
to the increased telomerase activity.88 miR-15a and miR-16,
which are under expressed in ovarian cell lines and in primary
ovarian tissues, directly target the 30 untranslated region
(UTR) and significantly correlate with Bmi-1 protein levels in
ovarian cancer patients and cell lines. Furthermore, Bmi-1
protein levels are downregulated in response to miR-15a or
miR-16 expression and cause significant reduction in ovarian
cancer cell proliferation and clonal growth.31
Prostate cancer: Bmi-1 is overexpressed in prostate
cancer with adverse pathologic and clinical features. Tu-
mors with higher Gleason scores have a significant upre-
gulation of Bmi-1, while the presence of Bmi-1 in lower
grade prostate cancer samples is highly predictive for
prostate-specific antigen recurrence.124 Microarray meta-
analyses have found that the presence of Bmi-1 in pros-
tate cancer specimens often indicates metastatic disease
and a high probability of unfavorable therapeutic
outcome.115 Bmi-1 has been shown enriched in a population
of prostate cancer cells with higher tumor initiating ca-
pacities.115 Bmi-1 inhibition protects prostate cells from
FGF10 driven hyperplasia and slows the growth of aggres-
sive PTEN-deletion induced prostate cancer.93
Nasopharyngeal carcinoma: Bmi-1 is overexpressed in
nasopharyngeal carcinoma cell lines at both mRNA and
protein levels. Overexpression of Bmi-1 was also observed
in a significant number of nasopharyngeal carcinomatumors, which correlated with advanced invasive stage of
the tumor progression and poor prognosis. Overexpression
of Bmi-1 led to induction of telomerase activity, reduction
of p16Ink4a expression and immortalization of nasopharyn-
geal epithelial cells.125 Bmi-1 plays an important role in the
pathogenesis of nasopharyngeal carcinoma by inducing EMT
partially by targeting the tumor suppressor PTEN, thus
activating the PI3K/Akt pathway. Upregulation of Bmi-1 led
to the stabilization of Snail, a transcriptional repressor
associated with EMT, via modulation of PI3K/Akt/GSK-3b
signaling.126
Head and neck cancer: Bmi-1 mediates its diverse ef-
fects through upregulation of the mitotic kinase Aurora A,
which is encoded by the AURKA gene. During Bmi-1-
overexpression, the b-catenin/TCF4 complex regulates
the transcription of AURKA.127 In patients with head and
neck cancers, increased levels of both Twist1 and Bmi-1
correlate with downregulation of E-cadherin and p16Ink4a,
and are associated with worse prognosis.128 In addition, in
head and neck squamous cell carcinoma (HNSCC) a CD44þ
fraction comprising of less than 10% of the tumor signifi-
cantly expresses nuclear Bmi-1 and demonstrates stem-like
properties by giving rise to tumor in vivo.129
Breast cancer: Breast cancer shows a high prevalence of
Bmi-1 expression, which is significantly correlated with
aggressive features and unfavorable prognosis. Bmi-1 plays
a crucial role in invasion and metastasis by modulating the
Akt/GSK-3b/Snail pathway and the expression of EMT
markers in breast cancer. Bmi-1 promotes the invasion and
234 R. Bhattacharya et al.metastasis of human breast cancer.130 Bmi-1 is critical to
the oncogenic behavior of several established breast cancer
cell lines in vitro and in vivo. Most importantly, the
collaboration of Bmi-1 and H-RAS in human mammary
epithelial cells leads to a highly aggressive phenotype that
includes increased spontaneous metastasis to the liver and
spleen, and novel metastasis to the brain.131
Colorectal cancer: Bmi-1 regulates histone ubiquitina-
tion in primary human colorectal cancer cells which plays
an important role in colon cancer proliferation in vitro and
in vivo.26 Kreso et al, recently reported for the first time
that the stemness function of CICs could be targeted with a
small-molecule inhibitor of Bmi-1.132 In human colorectal
cancer, CIC function is dependent on the canonical self-
renewal regulator Bmi-1. Downregulation of Bmi-1 in-
hibits the self-renewal property of colorectal CICs, and
thus abrogates their tumorigenic potential. Bmi-1 inhibitor
treatment in primary colorectal cancer xenografts also
resulted in colorectal CIC loss with long-term and irre-
versible impairment of tumor growth. Targeting the
Bmi-1-related self-renewal machinery provides the frame-
work for clinical evaluation of anti-Bmi-1 therapy not only
in colorectal cancer but other cancers such as ovarian
cancer which are characterized by frequent relapse after
chemotherapy.
Hepatocellular carcinoma: Bmi-1 is upregulated in
HCC.133 Bmi-1 can cooperate with other oncogenic signals
to promote hepatic carcinogenesis in vivo. Bmi-1 functions
independent of Ink4A/Arf repression in liver cancer
development.72
Intestinal cancer: Bmi-1 deficiency impairs the pro-
gression and maintenance of small intestinal tumors in a
cell autonomous and highly Arf-dependent manner. Bmi-1
loss reduces both the number and size of small intestinal
adenomas.134
Leukemia: High expression of Bmi-1 in acute myeloid
leukemia cells is associated with an unfavorable prog-
nosis.135 Expression of Bmi-1 is required for maintenance
and self-renewal of normal and leukemic stem and pro-
genitor cells, and protects cells against oxidative stress.136
Also, Bmi-1 has an essential role in maintaining the self-
renewing capacity of leukemic stem cells.137
Lung cancer: Bmi-1 is required for the self-renewal of
ASCs including the lung epithelial stem cells, bron-
chioalveolar stem cells (BASCs).138,139 Bmi-1 knockout mice
exhibited an impaired ability to repair Clara cell injury that
was associated with failure of BASC expansion in vivo.14,138
Skin cancer: Bmi-1 plays an important role in main-
taining proliferation of basal keratinocytes and in main-
taining the viability. Bmi-1 levels are distinctly elevated in
immortalized and transformed epidermis-derived cell lines
and in epidermal squamous cell carcinoma of suprabasal
differentiating keratinocytes.140
Tongue cancer: Bmi-1 is aberrantly overexpressed in a
significant portion of tongue cancers. Elevated Bmi-1 is
associated with cervical node metastasis. Bmi-1 serves as a
key driver with multiple oncogenic functions during tongue
cancer progression and as a novel biomarker for diagnosis
and prognostic prediction for patients.141
The exhaustive above list of malignancies where Bmi-1
acts as an oncoprotein can be expected to be expanded as
research progresses. Given the wide variety of cancersranging from solid tumors to glioblastoma to leukemia,
where Bmi-1 is implicated and its involvement in mainte-
nance of CSC’s that are chemoresistant makes Bmi-1 a po-
tential candidate for drug therapy.Conclusion and future directions
Bmi-1 is at an important crossroad in at least 16 different
types of cancer and stands out as a promising target in the
small list of genes known to regulate CSC function. Thus,
Bmi-1 is an important new target for therapy in malig-
nancies characterized by overexpression of Bmi-1. How-
ever, since no direct enzymatic activity of Bmi-1 has yet
been established, developing a small molecule inhibitor
that directly targets Bmi-1 poses a pharmacological
challenge.
However in principle, several independent groups have
investigated the effect of reducing Bmi-1 levels in vitro and
in vivo in different cancers ranging from ovarian to pros-
trate and these studies have validated Bmi-1 as a thera-
peutic target. Our previous study on ovarian cancer has
argued in favor of anti-Bmi-1 therapy in clinical settings due
to enhanced cisplatin sensitivity upon Bmi-1 silencing.76
Also downregulation of Bmi-1 leads to de-repression of
Ink4a, which encodes tumor suppressors p16Ink and p19Arf
that regulate senescence and apoptosis.18 Activation of
these pathways has been invoked as important tumor sup-
pressors, because these pathways act as potent inhibitors
of proliferation or propagation of damaged cells. In addi-
tion, we posit that cisplatin and Bmi-1 act on similar
pathways affecting mitochondrial function and/or through
increased ROS generation, causing DNA damage augmenting
the signal initiating apoptosis.76 As noted above in the
context of various cancers, different miRs target the Bmi-1
mRNA, and we have shown that miR15a/16 significantly
reduce Bmi-1 levels and subsequent clonal growth in
ovarian cancer cells.31 In vivo silencing of Bmi-1 by siRNA
delivered using DOPC (1,2-dioleoyl-sn-glycero-3-
phosphatidylc holine) nanoliposomes in the orthotopic
A2780-CP20 mouse model resulted in significant reduction
in tumor weight and nodules compared to the control siRNA
group. Combination therapy with Bmi-1 siRNA and cisplatin
resulted in even greater reduction in tumor weight and
nodule.76 Therefore, though siRNA or miRNA approaches
against Bmi-1 might prove useful in therapy, delivery and
off-target effects remain of considerable concern. In this
context, several known drugs have been reported to reduce
Bmi-1 expression. For example, Bommi et al, and Jung
et al, independently investigated the effects of HDACi on
Bmi-1 expression and downstream targets.29 HDACi treat-
ment downregulated PcG genes such as Bmi-1, EZH2 and
SUZ12 in senescent mesenchymal stem cells.142 This was
associated with hypophosphorylation of Rb, which causes
Rb to bind and decrease the transcriptional activity of E2F
and cellular senescence by p16Ink4a regulation.142 Blocking
Bmi-1 expression by HDACi in immortal non-transformed
breast epithelial cells and breast cancer cells was accom-
panied by a decrease in histone-2A Lys119 ubiquitination
(H2AK119Ub), de-repression of growth inhibitory genes and
putative tumor suppressors, which are known to be silenced
by PcG proteins and PRCs.29
Bmi-1: A comprehensive review 235Recently, the drug Artemisinin was also shown to inhibit
the expression of Bmi-1. Artemisinin and its derivatives are
particularly useful for the treatment of resistant Plasmo-
dium falciparum malarial parasites. This drug has an
endoperoxide group that is activated by intraparasitic
hemeeiron to form free radicals, which kill malarial para-
sites by alkylating biomolecules. Artemisinin inhibited Bmi-
1 at both protein and transcriptional levels. Bmi-1 knock-
down made the cells more sensitive to Artemisinin with an
increase in accumulation at the G1-phase of the cell
cycle.143 However, none of these drugs can be claimed to
be a specific Bmi-1 inhibitor and therefore run the risk of
bystander effect when evaluated from a clinical
perspective.
In this regard PTC Therapeutics (NJ) has attempted to
exploit the possible post-transcriptional regulation of Bmi-1
in a bid to screen for Bmi-1 specific drugs. The Bmi-1 30-UTR
contains multiple AeU rich elements that can significantly
upregulate reporter gene expression, while its 50-UTR con-
tains a strong IRES activity. High-throughput screening using
compounds that selectively inhibited 50- and 30- UTR-
mediated Bmi-1 reporter expression identified PTC-209,
which subsequently inhibited endogenous Bmi-1 expression
in human colorectal HCT116 and human fibrosarcoma
HT1080 tumor cells in a dose- and time- dependent manner
(IC50 at about 0.5 mM).
132 Cytotoxicity was ruled out since
PTC-209 did not inhibit cell growth or viability in HEK293
human embryonic kidney cells after overnight treatment
and had limited effects on cell proliferation in HT1080 cells
after a 48-h treatment. That PTC-209 modulated the Bmi-1-
PRC1 complex activity was evident from reduced global
ubiquitinated histone H2A with no effect on total H2A or
RING1A levels. PTC-209 selectively lowered Bmi-1 levels
and decreased colorectal tumor cell growth. Further, unlike
the genetic manipulation, PTC-209 provided the control to
modulate the length and extent of Bmi-1 inhibition through
the addition or removal of the inhibitor, a critical tool to
further investigate the effects of Bmi-1 function in various
cancers.132 Thus the future of anti-Bmi-1 therapy holds
promise and development of kinase specific inhibitors that
affect specific phosphorylation sites on Bmi-1 can be
envisioned.
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